Daniel M Labow, MD Email Daniel Labow

Daniel M. Labow, M.D., Chief of the Surgical Oncology Division at Mount Sinai Hospital, is a board-certified Surgeon with a specialty in Surgical Oncology.  He has established himself at Mount Sinai Hospital since 2004 after studying medicine at a unique, combined medical school, the Dartmouth-Brown Medical Program, completing his General Surgery residency at the University of Chicago, and receiving his fellowship training at Memorial Sloan-Kettering Cancer Center.  As Vice Chair of Outpatient Services for the Department of Surgery, Dr. Labow continuously designs processes to facilitate unprecedented patient care.  Furthermore he instills this practice on the new generation of physicians while working tirelessly to advance the educational program at Mount Sinai Hospital by being the Program Director of Surgical Oncology Fellowship.

During the length of his trainings, as well as 2 additional years post residency, Dr. Labow pursued extensive clinical and basic science research.  His clinical and research interests include the diagnosis and treatment of a broad range of both primary and metastatic malignancies including gastric and esophageal cancer, pancreatic neoplasms, primary and metastatic liver malignancies, biliary tract disease, colon and rectal cancer, sarcoma, and melanoma.  Dr. Labow’s devotion to research and training allow him to understand the entire spectrum of treatments for these cancers, including investigational approaches to help guide each individual patient along the appropriate treatment unique pathway.  Moreover, he concentrates in the application of minimally invasive techniques and their role in cancer care. 

At Mount Sinai Hospital, Dr. Labow established and directs one of the busiest Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) programs in the country.  This technique, which combines surgery with chemotherapy, has revolutionized the treatment of cancers in the abdominal (peritoneal) lining that stem from colon, gastric, ovarian, and appendiceal cancers, as well as mesothelioma and pseudomyxoma peritonei.  HIPEC is essentially a chemotherapy "bath" that delivers heated chemotherapy directly into the abdominal cavity, where it penetrates the diseased tissue directly.  This targeted contact of the heated drug kills the tumor nodules, which increases absorption of the chemotherapy solution.  Dr. Labow, who has performed more than 220 HIPEC procedures since 2007, recognizes the vitality the combination procedure has in significantly extending patient survival rates whilst minimizing the known side effects of chemotherapy that are normally administered intravenously.  Additionally, it destroys undetected cancer cells after the tumor has been removed, preventing them from forming into new tumors and causing a reoccurrence of cancer.

Dr. Daniel Labow’s rapport with his patients, his medical knowledge and his dedication as a physician contribute to his reputation with patients as well as other physicians.  He is an active member in a number of physician organizations including the American College of Surgeons, American Hepatopancreaticobiliary Association, and Society of Surgical Oncology where he sits on the education committee.  As New York State Chair of the Commission on Cancer, Dr. Labow helps shape future cancer initiatives and policy, in addition to Co-Chairing the Gastrointestinal Disease Focus Group at Mount Sinai Hospital.  Dr. Labow has been awarded the Robert Paradny Teaching award and was recently named one of New York Metro Area’s Top Doctors by Castle Connolly. 

In the News:
CBS Evening News interviews Dr. Labow about rising colorectal cancer cases in young adults


Dr. Labow shares the incredible story of a Holocaust survivor who also beat cancer